Elinzanetant is under clinical development by Bayer and currently in Phase III for Vasomotor Symptoms of Menopause (Hot Flashes). According to GlobalData, Phase III drugs for Vasomotor Symptoms of Menopause (Hot Flashes) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Elinzanetant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Elinzanetant is under development for the treatment of sex hormone-related conditions in women such as vasomotor symptoms of menopause (hot flashes). It is a capsule formulation administered orally. NT-814 is a small molecule that acts by targeting NK-1 and NK-3 receptors. It was also under development for the treatment of schizophrenia and for the treatment of central nervous system disorders such as opiate use disorder.
Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
For a complete picture of Elinzanetant’s drug-specific PTSR and LoA scores, buy the report here.